FY2024 Earnings Estimate for MGRM Issued By Roth Capital

Monogram Orthopaedics, Inc. (NASDAQ:MGRM) – Analysts at Roth Capital issued their FY2024 EPS estimates for Monogram Orthopaedics in a research note issued to investors on Monday, December 9th. Roth Capital analyst J. Wittes anticipates that the company will post earnings per share of ($0.50) for the year. Roth Capital currently has a “Strong-Buy” rating on the stock. The consensus estimate for Monogram Orthopaedics’ current full-year earnings is ($0.48) per share. Roth Capital also issued estimates for Monogram Orthopaedics’ Q4 2024 earnings at ($0.12) EPS, Q1 2025 earnings at ($0.11) EPS, Q2 2025 earnings at ($0.11) EPS, Q3 2025 earnings at ($0.11) EPS, Q4 2025 earnings at ($0.15) EPS, FY2025 earnings at ($0.49) EPS, Q1 2026 earnings at ($0.12) EPS, Q2 2026 earnings at ($0.13) EPS, Q3 2026 earnings at ($0.10) EPS, FY2026 earnings at ($0.49) EPS, FY2027 earnings at ($0.28) EPS and FY2028 earnings at $0.06 EPS.

Separately, Roth Mkm assumed coverage on shares of Monogram Orthopaedics in a research note on Monday. They set a “buy” rating and a $4.00 target price on the stock.

Monogram Orthopaedics Price Performance

MGRM stock opened at $2.68 on Wednesday. Monogram Orthopaedics has a 1-year low of $1.53 and a 1-year high of $4.90. The business has a fifty day moving average price of $2.26 and a 200-day moving average price of $2.39. The stock has a market capitalization of $91.95 million, a P/E ratio of -5.70 and a beta of 2.01.

Institutional Investors Weigh In On Monogram Orthopaedics

Several hedge funds and other institutional investors have recently made changes to their positions in MGRM. Barclays PLC purchased a new stake in Monogram Orthopaedics during the third quarter valued at approximately $29,000. Geode Capital Management LLC grew its stake in shares of Monogram Orthopaedics by 1,267.4% during the 3rd quarter. Geode Capital Management LLC now owns 210,144 shares of the company’s stock valued at $557,000 after acquiring an additional 194,776 shares during the period. Finally, State Street Corp bought a new stake in Monogram Orthopaedics during the 3rd quarter worth approximately $62,000. Hedge funds and other institutional investors own 0.45% of the company’s stock.

Monogram Orthopaedics Company Profile

Monogram Orthopaedics, Inc focuses on developing a product solution architecture to enable patient-optimized orthopaedic implants. The company intends to produce and market robotic surgical equipment and related software, orthopedic implants, tissue ablation tools, navigation consumables, and other miscellaneous instrumentation for use in reconstructive joint replacement procedures.